Skip to main content
bronchiolus_querschnitt_helmholtz_1920x640px
Helmholtz Munich

Fernandez Lab

Immune networks in chronic lung diseases

Our scientific focus is to understand the contribution of the immune system to organ fibrosis. Fibrosis is a common final outcome of most chronic inflammatory diseases, especially chronic lung diseases.

Our scientific focus is to understand the contribution of the immune system to organ fibrosis. Fibrosis is a common final outcome of most chronic inflammatory diseases, especially chronic lung diseases.

Fibrosis - incurable and limited therapies

To date, as many as 45% of all deaths in the developed world are related to pathological tissue remodeling. Chronic lung diseases (CLD) are the 3rd leading cause of death worldwide. Among CLD, Idiopathic Pulmonary Fibrosis (IPF) is a chronic and lethal fibroproliferative disease of the lung, with unknown etiology. IPF is characterized by progressive fibrosis and irreversible loss of lung function, with a median survival, or time to lung transplantation, of about 3 years after diagnosis. In many organs, innate and adaptive immunity contributes to fibrogenesis. Rising evidence shows that abnormal immune responses are implicated in IPF pathophysiology.

Project details

  • Functional assessment of interactions between mononuclear myeloid cells and lung structural cells
  • Identification of key ligand/receptor interactions in immune-structural lung cell crosstalk
  • Molecular characterization of in immune-structural lung cell interaction
  • Target evaluation in in-vitro models

Scientists at Fernandez Lab

Asarian_Loredana_LHI_Portrait

Dr. Loredana Asarian

Postdoc

Benteng Deng

PhD Student

Daniela Dietel

Lab Manager

Dr. Andrea Schamberger

Post Doctoral Fellow
Portrait Dmytro Sirokha LHI

Dmytro Sirokha

Master Student
Portrait Lilith Trassl LHI

Lilith Trassl

Doctoral Student

Contact

Isis Fernandez Mitarbeiterfoto LHI

Dr. Isis E. Fernandez

Team Leader